DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

Software innovations for patient-specific theranostics and molecular radiotherapy Trends that will impact the future of medicine

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

Theranostics continue to gain momentum Investments ramp up but challenges remain

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

Mobile PET relieves hardship for rural cancer patients Mobile PET isn't just good medicine, it's good business

In nuclear medicine, scanners get more sensitive, software more specific What's new in PET and SPECT?

Amyloid PET scans help with Alzheimer's clinical management

par Thomas Dworetzky , Contributing Reporter
Getting brain scans for Alzheimer's hallmark amyloid plaque “significantly influenced clinical management of patients with mild cognitive impairment and dementia,” a nation-wide study has found.

"We are impressed by the magnitude of these results, which make it clear that amyloid PET imaging can have a major impact on how we diagnose and care for patients with Alzheimer's disease and other forms of cognitive decline," study lead author and principal investigator Dr. Gil Rabinovici, professor of Neurology at the UCSF Memory and Aging Center and member of the UCSF Weill Institute for Neurosciences, said in a statement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The multicenter study of over 11,000 Medicare recipients, published in JAMA, showed that in 60 percent of cases clinicians armed with PET scan results changed both the use of medication and counseling for mild cognitive impairment and dementia. That was double the impact predicted by researchers. The effort involved scientists from the Alzheimer's Association, UC San Francisco, Brown University School of Public Health, Virginia Commonwealth University School of Public Health, Washington University School of Medicine in St. Louis, UC Davis School of Medicine, and the Kaiser Permanente Division of Research, and was managed by the American College of Radiology.

The researchers concluded that the use of amyloid PET was associated with clinical management changes within 90 days, they reported in the journal.

"These results present highly credible, large-scale evidence that amyloid PET imaging can be a powerful tool to improve the accuracy of Alzheimer's diagnosis and lead to better medical management, especially in difficult-to-diagnose cases," suggested Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and a coauthor of the study. "It is important that amyloid PET imaging be more broadly accessible to those who need it."

While there is no cure for the devastating cognitive decline, catching it early permits patients, families and their healthcare providers to tackle such crucial issues as safety and care-planning for the future – and if no plaque is found on PET scan, it can also lead to identifying other, potentially reversible, causes of memory loss.

The tracers used are FDA approved, but at present Medicare and health insurance plans do not cover amyloid PET imaging to aid in dementia diagnosis, according to researchers.

The results come from the Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) study that enlisted the aid of almost 1,000 dementia specialists at 595 sites in the U.S.
  Pages: 1 - 2 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

La publicité d'email
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Jobs/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Voir les utilisateurs récemment certifiés
Voir les utilisateurs récemment certifiés
Récemment évalué sur DOTmed
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service Technicians Forum
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS